Drugs / Anti-lymphocyte globulin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06695741 | Nov 2024 → Feb 2027 expected | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT05975996 | Jul 2023 → Dec 2024 overdue | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02461121 Comparator | May 2004 → May 2013 | acute myeloid leukemia | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-lymphocyte globulin | “Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment.” NCT05975996 ↗2“Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment” NCT06695741 ↗ |